Who are Tekturna's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Capozide 25/15, Aliskiren Hydrochlorothiazide, ALIS, Aliskiren, Perindopril, Valsartan/aliskiren, Early sequential nephron blockade.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aliskiren.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Tekturna — Competitive Intelligence Brief

Tekturna (ALISKIREN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Renin Inhibitor. Area: Cardiovascular.

marketed Renin Inhibitor Renin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Tekturna (ALISKIREN) — Lxo Ireland. Tekturna works by blocking the renin enzyme, which is involved in the production of angiotensin II, a potent vasoconstrictor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tekturna TARGET	ALISKIREN	Lxo Ireland	marketed	Renin Inhibitor	Renin	2007-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Aliskiren Hydrochlorothiazide	Aliskiren Hydrochlorothiazide	Novartis	marketed	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter (NCCT)
ALIS	ALIS	Lxo Ireland	marketed		Multidrug resistance protein 1, Cytochrome P450 3A4, Renin
Aliskiren, Perindopril	Aliskiren, Perindopril	Medical University of Gdansk	marketed	Antihypertensive combination (direct renin inhibitor + ACE inhibitor)	Renin and Angiotensin-Converting Enzyme (ACE)
Valsartan/aliskiren	Valsartan/aliskiren	Novartis	marketed	Angiotensin II receptor blocker + direct renin inhibitor combination	AT1 receptor (valsartan); renin (aliskiren)
Early sequential nephron blockade	Early sequential nephron blockade	University of Parma	marketed	RAAS inhibitor combination strategy	Renin-angiotensin-aldosterone system (multiple targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Renin Inhibitor class)

Lxo Ireland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tekturna — Competitive Intelligence Brief. https://druglandscape.com/ci/aliskiren. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab